Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03522246




Registration number
NCT03522246
Ethics application status
Date submitted
9/04/2018
Date registered
11/05/2018
Date last updated
15/09/2023

Titles & IDs
Public title
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Scientific title
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Secondary ID [1] 0 0
2017-004557-17
Secondary ID [2] 0 0
CO-338-087/GOG-3020/ENGOT-ov45
Universal Trial Number (UTN)
Trial acronym
ATHENA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Epithelial Ovarian Cancer 0 0
Primary Peritoneal 0 0
Fallopian Tube Cancer 0 0
Newly Diagnosed 0 0
FIGO Stage III-IV 0 0
Partial Response 0 0
Complete Response 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rucaparib
Treatment: Drugs - Nivolumab
Treatment: Drugs - Placebo Oral Tablet
Treatment: Drugs - Placebo IV Infusion

Experimental: Arm A - oral rucaparib + intravenous (IV) nivolumab

Experimental: Arm B - oral rucaparib+IV placebo

Experimental: Arm C - oral placebo+ IV nivolumab

Placebo Comparator: Arm D - Oral placebo + IV placebo


Treatment: Drugs: Rucaparib
Oral rucaparib will be administered twice daily

Treatment: Drugs: Nivolumab
IV nivolumab will be administered once every 4 weeks

Treatment: Drugs: Placebo Oral Tablet
Placebo tablets will be administered twice daily

Treatment: Drugs: Placebo IV Infusion
IV placebo will be administered once every 4 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Investigator assessed Progression-free survival (PFS)
Timepoint [1] 0 0
From randomization until disease progression (up to approximately 7 years)
Secondary outcome [1] 0 0
Blinded independent central review (BICR) PFS
Timepoint [1] 0 0
Every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
From enrollment to primary study completion of study (up to approximately 10 years)
Secondary outcome [3] 0 0
Objective response rate (ORR)
Timepoint [3] 0 0
For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years
Secondary outcome [4] 0 0
Duration of response (DOR)
Timepoint [4] 0 0
For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years
Secondary outcome [5] 0 0
Number of participants with treatment-emergent Adverse Events (AEs) as assessed by CTCAE v4 (or higher) as a measure of safety and tolerability
Timepoint [5] 0 0
Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)
Secondary outcome [6] 0 0
Number of participants with serious AEs as a measure of safety and tolerability
Timepoint [6] 0 0
Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)
Secondary outcome [7] 0 0
Number of participants with laboratory abnormalities as a measure of safety and tolerability
Timepoint [7] 0 0
Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)

Eligibility
Key inclusion criteria
- Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or
primary peritoneal cancer.

- Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy
and partial omentectomy, either prior to chemotherapy (primary surgery) or following
neoadjuvant chemotherapy (interval debulking)

- Completed first-line platinum-based chemotherapy and surgery with a response, in the
opinion of the Investigator

- Sufficient tumor tissue for planned analysis

- ECOG performance status of 0 or 1

- Patients must be 20 years of age to consent in Japan, Taiwan and South Korea; in all
other participating countries patients must be 18 years of age to consent
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Pure sarcomas or borderline tumors or mucinous tumors

- Active second malignancy

- Known central nervous system brain metastases

- Any prior treatment for ovarian cancer, other than the first-line platinum regimen

- Evidence of interstitial lung disease or active pneumonitis

- Active, known or suspected autoimmune disease

- Condition requiring active systemic treatment with either corticosteroids (>10 mg
daily prednisone equivalent) or other immunosuppressive medications

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/05/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/12/2030
Actual
Sample size
Target
1000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Newcastle Private Hospital - New Lambton Heights
Recruitment hospital [2] 0 0
Northern Cancer Institute St Leonards - Saint Leonards
Recruitment hospital [3] 0 0
Prince of Wales Hospital - Sydney
Recruitment hospital [4] 0 0
Westmead Hospital - Westmead
Recruitment hospital [5] 0 0
Royal Brisbane and Women's Hospital - Brisbane
Recruitment hospital [6] 0 0
Brian Fricker Oncology Centre, Burnside Hospital - Toorak Gardens
Recruitment hospital [7] 0 0
Peter MacCallum Cancer Center - Melbourne
Recruitment hospital [8] 0 0
St John of God Subiaco Hospital - Subiaco
Recruitment postcode(s) [1] 0 0
2145 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [3] 0 0
2031 - Sydney
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment postcode(s) [5] 0 0
4020 - Brisbane
Recruitment postcode(s) [6] 0 0
5065 - Toorak Gardens
Recruitment postcode(s) [7] 0 0
3000 - Melbourne
Recruitment postcode(s) [8] 0 0
6005 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
Nevada
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Dakota
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Utah
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Wisconsin
Country [32] 0 0
Belgium
State/province [32] 0 0
Leuven
Country [33] 0 0
Canada
State/province [33] 0 0
Alberta
Country [34] 0 0
Canada
State/province [34] 0 0
British Columbia
Country [35] 0 0
Canada
State/province [35] 0 0
Manitoba
Country [36] 0 0
Canada
State/province [36] 0 0
Nova Scotia
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
Czechia
State/province [39] 0 0
Brno
Country [40] 0 0
Czechia
State/province [40] 0 0
Prague
Country [41] 0 0
Czechia
State/province [41] 0 0
Zlín
Country [42] 0 0
Denmark
State/province [42] 0 0
Aalborg
Country [43] 0 0
Denmark
State/province [43] 0 0
Odense
Country [44] 0 0
Finland
State/province [44] 0 0
Kuopio
Country [45] 0 0
Germany
State/province [45] 0 0
Dessau
Country [46] 0 0
Germany
State/province [46] 0 0
Duesseldorf
Country [47] 0 0
Germany
State/province [47] 0 0
Heidelberg
Country [48] 0 0
Germany
State/province [48] 0 0
Mannheim
Country [49] 0 0
Germany
State/province [49] 0 0
Traunstein
Country [50] 0 0
Greece
State/province [50] 0 0
Athens
Country [51] 0 0
Greece
State/province [51] 0 0
Patra
Country [52] 0 0
Greece
State/province [52] 0 0
Thessaloniki
Country [53] 0 0
Ireland
State/province [53] 0 0
Cork
Country [54] 0 0
Ireland
State/province [54] 0 0
Limerick
Country [55] 0 0
Ireland
State/province [55] 0 0
Waterford
Country [56] 0 0
Israel
State/province [56] 0 0
Jerusalem
Country [57] 0 0
Israel
State/province [57] 0 0
Kfar Saba
Country [58] 0 0
Israel
State/province [58] 0 0
Nahariya
Country [59] 0 0
Israel
State/province [59] 0 0
Ramat Gan
Country [60] 0 0
Israel
State/province [60] 0 0
Safed
Country [61] 0 0
Israel
State/province [61] 0 0
Tel Aviv
Country [62] 0 0
Italy
State/province [62] 0 0
Aviano
Country [63] 0 0
Italy
State/province [63] 0 0
Candiolo
Country [64] 0 0
Italy
State/province [64] 0 0
Catania
Country [65] 0 0
Italy
State/province [65] 0 0
Chieti
Country [66] 0 0
Italy
State/province [66] 0 0
Napoli
Country [67] 0 0
Italy
State/province [67] 0 0
Roma
Country [68] 0 0
Italy
State/province [68] 0 0
Vicenza
Country [69] 0 0
Japan
State/province [69] 0 0
Amakubo
Country [70] 0 0
Japan
State/province [70] 0 0
Chiba
Country [71] 0 0
Japan
State/province [71] 0 0
Fukuoka
Country [72] 0 0
Japan
State/province [72] 0 0
Fukuura
Country [73] 0 0
Japan
State/province [73] 0 0
Gunma
Country [74] 0 0
Japan
State/province [74] 0 0
Hiroshima
Country [75] 0 0
Japan
State/province [75] 0 0
Hyogo
Country [76] 0 0
Japan
State/province [76] 0 0
Iwate
Country [77] 0 0
Japan
State/province [77] 0 0
Kanagawa
Country [78] 0 0
Japan
State/province [78] 0 0
Namiki
Country [79] 0 0
Japan
State/province [79] 0 0
Osaka
Country [80] 0 0
Japan
State/province [80] 0 0
Saitama
Country [81] 0 0
Japan
State/province [81] 0 0
Shinanomachi
Country [82] 0 0
Japan
State/province [82] 0 0
Tokyo
Country [83] 0 0
Japan
State/province [83] 0 0
Takamatsu
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Gyeonggi-do
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Seoul
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Cheonan
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Suwon-si
Country [88] 0 0
New Zealand
State/province [88] 0 0
Auckland
Country [89] 0 0
New Zealand
State/province [89] 0 0
Christchurch
Country [90] 0 0
New Zealand
State/province [90] 0 0
Hamilton
Country [91] 0 0
New Zealand
State/province [91] 0 0
Palmerston North
Country [92] 0 0
New Zealand
State/province [92] 0 0
Tauranga
Country [93] 0 0
Poland
State/province [93] 0 0
Kondratowicza
Country [94] 0 0
Poland
State/province [94] 0 0
Bialystok
Country [95] 0 0
Poland
State/province [95] 0 0
Gdynia
Country [96] 0 0
Poland
State/province [96] 0 0
Lublin
Country [97] 0 0
Poland
State/province [97] 0 0
Poznan
Country [98] 0 0
Poland
State/province [98] 0 0
Szczecin
Country [99] 0 0
Romania
State/province [99] 0 0
Jud. Bihor
Country [100] 0 0
Romania
State/province [100] 0 0
Jud. Cluj
Country [101] 0 0
Romania
State/province [101] 0 0
Baia Mare
Country [102] 0 0
Romania
State/province [102] 0 0
Bucuresti
Country [103] 0 0
Romania
State/province [103] 0 0
Cluj-Napoca
Country [104] 0 0
Romania
State/province [104] 0 0
Craiova
Country [105] 0 0
Romania
State/province [105] 0 0
Iasi
Country [106] 0 0
Romania
State/province [106] 0 0
Ploiesti
Country [107] 0 0
Romania
State/province [107] 0 0
Suceava
Country [108] 0 0
Romania
State/province [108] 0 0
Timisoara
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Arkhangel'sk
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Omsk
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Orenburg
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Pesochnyy
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Pyatigorsk
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Saint Petersburg
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Saransk
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Sotchi
Country [117] 0 0
Singapore
State/province [117] 0 0
Singapore
Country [118] 0 0
Spain
State/province [118] 0 0
Barcelona
Country [119] 0 0
Spain
State/province [119] 0 0
Bilbao
Country [120] 0 0
Spain
State/province [120] 0 0
Castillón
Country [121] 0 0
Spain
State/province [121] 0 0
El Palmar
Country [122] 0 0
Spain
State/province [122] 0 0
Jerez de la Frontera
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid
Country [124] 0 0
Spain
State/province [124] 0 0
Oviedo
Country [125] 0 0
Spain
State/province [125] 0 0
Palma De Mallorca
Country [126] 0 0
Spain
State/province [126] 0 0
Sevilla
Country [127] 0 0
Sweden
State/province [127] 0 0
Linköping
Country [128] 0 0
Sweden
State/province [128] 0 0
Lund
Country [129] 0 0
Sweden
State/province [129] 0 0
Stockholm
Country [130] 0 0
Taiwan
State/province [130] 0 0
Hualien City
Country [131] 0 0
Taiwan
State/province [131] 0 0
Kaohsiung
Country [132] 0 0
Taiwan
State/province [132] 0 0
New Taipei City
Country [133] 0 0
Taiwan
State/province [133] 0 0
Taichung
Country [134] 0 0
Taiwan
State/province [134] 0 0
Tainan
Country [135] 0 0
Taiwan
State/province [135] 0 0
Taipei
Country [136] 0 0
Taiwan
State/province [136] 0 0
Taoyuan
Country [137] 0 0
Turkey
State/province [137] 0 0
Ankara
Country [138] 0 0
Turkey
State/province [138] 0 0
Istanbul
Country [139] 0 0
Turkey
State/province [139] 0 0
Manisa
Country [140] 0 0
Turkey
State/province [140] 0 0
Yuregir
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Kent
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Northampton
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Brighton
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Bristol
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Cambridge
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Edinburgh
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Lancaster
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Leeds
Country [149] 0 0
United Kingdom
State/province [149] 0 0
London
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Middlesbrough
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Poole
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Swansea
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Taunton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
pharmaand GmbH
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Gynecologic Oncology Group
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Commercial sector/Industry
Name [4] 0 0
Foundation Medicine
Address [4] 0 0
Country [4] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm
study evaluating rucaparib and nivolumab as maintenance treatment following response to
front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will
be analyzed based on homologous recombination (HR) status of tumor samples.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03522246
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03522246